NR1H4 and steatosis: Also, our data are in line with previous data on metabolic, anti-inflammatory and anti-fibrotic effects of FXR agonist treatment, including OCA, in other rodent models of obesity with features of simple steatosis/low-grade inflammation22,48 and NASH49, as well as in nutrient-deficient dietary50–52 and surgery-based models of NASH51.